An expanded intervention study of Jusvinza benefiting moderately to severely active patients with rheumatoid arthritis recently began in the Eastern Province of Cuba and Camagüey.
The drug, a Cuban product designed to treat autoimmune diseases, will be given to patients participating in the study as injections for six months. Four doses of the vaccine will be given during the first month of treatment, once a week and then once a month. for the remaining five months.
Dr. Alberto Alberteris Rodríguez, the leader of this study in Holguin, said, “After an evaluation of the cases in April this year, candidate patients were selected to participate in the intervention study. They underwent corresponding supplementary examinations and, after confirmation that they met the inclusion criteria, were They were used on the ninth day. “As required by the protocol, they had to undergo medical observation for three hours. “
READ ALSO: They plan an expanded intervention study for rheumatoid arthritis in Holguin
Rheumatoid arthritis is a chronic inflammatory disease in which the immune system attacks its own tissues, including joints, including those of the hands and feet.
Jusvinza is a Cuban biotech product composed of 27 amino acid molecules with anti-inflammatory and immune response modulating effects.
The product is currently in the third phase of clinical trials in Havana, while an expanded intervention study is underway in the east of the country and in Camaguey, which has been named “Marianna” in honor of Mariana, Mother of the Country. Grajales, head of the Department of Rheumatology at Lucia Hospital because of rheumatoid arthritis, also pointed out that arthritis is a major disease in women.
Jusvinza has previously been used to treat COVID-19 in patients with high levels of inflammation in addition to rheumatoid arthritis, and its use in diseases such as community-acquired pneumonia is advancing.
